Century Therapeutics Stock (NASDAQ:IPSC)
Previous Close
$1.04
52W Range
$0.95 - $5.51
50D Avg
$1.34
200D Avg
$2.30
Market Cap
$85.03M
Avg Vol (3M)
$549.05K
Beta
1.42
Div Yield
-
IPSC Company Profile
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| BPMC | Blueprint Medicines Corporation |
| MLYS | Mineralys Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| PASG | Passage Bio, Inc. |
| NKTX | Nkarta, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| KZR | Kezar Life Sciences, Inc. |
| GBIO | Generation Bio Co. |
| KROS | Keros Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |